{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004036","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.583099+00:00","generated_at":"2026-05-18T23:23:00.086830+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Harvard Bioscience out of compliance with Nasdaq audit committee rule after board resignation","bullets":["Notified Nasdaq on June 18, 2025 of non-compliance with Listing Rule 5605(c)(2)(A) due to Alan Edrick's resignation.","Audit Committee now has only two members; one vacancy from Edrick's departure effective June 10, 2025.","Cure period runs until earlier of next annual meeting or June 10, 2026; company plans to appoint independent director."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004036","json":"https://secwatch.observer/filing/0001171843-25-004036.json","markdown":"https://secwatch.observer/filing/0001171843-25-004036.md","text":"https://secwatch.observer/filing/0001171843-25-004036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325004036/0001171843-25-004036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325004036/f8k_062325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:23:00.086830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da8ff9f1ce9b3c93c0a16def4029891bd18644ae","claim":"HARVARD BIOSCIENCE INC received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).","evidence_excerpt":"June 18, 2025, Harvard Biosci e nce, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement set forth in Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Composition Requirement”) due to the Company having only two members on the audit committee (the “Audit Committee”) of its Board of Directors (the “Board”). The Company’s current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick’s resignation from the Board and the Audit Committee effe","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325004036/0001171843-25-004036-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605(c)(2)(A), 5605(c)(4)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}